{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:18:26Z","timestamp":1767921506768,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clml.2014.02.010","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T01:50:03Z","timestamp":1393638603000},"page":"277-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma"],"prefix":"10.1016","volume":"14","author":[{"given":"John D.","family":"Hainsworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Raefsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana S.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Lunin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"James","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raven","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"DeBusk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.02.010_bib1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.010_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6","article-title":"Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma","author":"Kahl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.010_bib3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.1999.01547.x","article-title":"Angiogenic growth factors and endostatin in non-Hodgkin lymphoma","volume":"106","author":"Bertolini","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.02.010_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1034\/j.1600-0609.2002.01609.x","article-title":"Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin lymphoma","volume":"68","author":"Niitsu","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.02.010_bib5","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Salven","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.010_bib6","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2004-01-0226","article-title":"Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in\u00a0vivo","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.010_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.010_bib8","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.010_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2014.02.010_bib10","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.02.010_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.02.010_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.3","article-title":"Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group","author":"Tewari","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.010_bib13","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1038\/bcj.2012.12","article-title":"Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model","volume":"2","author":"Mori","year":"2012","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2014.02.010_bib14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","article-title":"A\u00a0phase 2 trial of standard-dose\u00a0cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large\u00a0B-cell non-Hodgkin lymphoma: SWOG 0515","volume":"120","author":"Stopeck","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.010_bib15","author":"Seymour","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.02.010_bib16","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.010_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized Intergroup trial of CHOP plus rituximab combined with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG SW0016","volume":"31","author":"Press","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.02.010_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rumnel","year":"2013","journal-title":"Lancet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:45Z","timestamp":1761870285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S2152265014000524"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.02.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}